Antibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BS4685 - Provider product page
- Provider
- Bioworld Technology, Inc
- Product name
- FANCA (phospho S1149) polyclonal antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic phosphopeptide derived from human FANCA around the phosphorylation site of Serine 1149.
- Description
- Fanconi anemia (FA) is an autosomal recessive disorder characterized by bone marrow failure, birth defects and chromosomal instability. At the cellular level, FA is characterized by spontaneous chromosomal breakage and a unique hypersensitivity to DNA cross-linking agents. At least eight complementation groups (A-G) have been identified and six FA genes (for subtypes A, C, D2, E, F and G) have been cloned. The FA proteins lack sequence homologies or motifs that could point to a molecular function. The cellular accumulation of FA proteins, including FANCA and FANCG, is subject to regulation by TNFÏ« signaling. Phosphorylation of FANC (Fanconi anemia complementation group) proteins is thought to be important for the function of the FA pathway. FANCA, also known as FACA and FANCH, associates with the Brm-related gene 1 (BRG1) product, a subunit of the SWI/SNF complex which remodels chromatin structure through a DNA-dependent ATPase activity. FANCA is mainly expressed in lymphoid tissues, testis and ovary. The amino-terminal region of the FANCA protein is required for FANCG binding, FANCC binding, nuclear localization and functional activity of the complex.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100ul
- Concentration
- 1 mg/ml
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
No comments: Submit comment
Supportive validation
- Submitted by
- Bioworld Technology, Inc (provider)
- Main image
- Experimental details
- Western blot (WB) analysis of p-FANCA (S1149) pAb at 1:500 dilutionLane1:HepG2 cell lysate treated with EGF(0.1ng/ML,30mins)Lane2:sp2/0 cell lysate treated with EGF(0.1ng/ML,30mins)Lane3:H9C2 cell lysate treated with EGF(0.1ng/ML,30mins)